Autolus Therapeutics (AUTL) Current Assets (2017 - 2026)
Autolus Therapeutics' (AUTL) quarterly Current Assets came in at $435.9 million in Q4 2025, down 34.05% YoY from $660.9 million in Q4 2024, and down 15.29% on a QoQ basis from $514.6 million in Q3 2025.
Autolus Therapeutics (AUTL) Current Assets (2017 - 2026) Analysis & Trends
Autolus Therapeutics (AUTL) has 9 years of Current Assets data on file, last reported at $435.9 million in Q4 2025.
- Quarterly Current Assets fell 34.05% year-over-year to $435.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $435.9 million (down 34.05% YoY) and the FY2025 annual result came in at $435.9 million, down 34.05% from the prior year.
- Current Assets eased to $435.9 million in Q4 2025, from $514.6 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $804.3 million in Q1 2024 to a low of $212.3 million in Q3 2022.
- A 5-year average of $438.2 million and a median of $374.6 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets tumbled 35.34% — and 2024, when it soared 140.07%.
- Tracing AUTL's Current Assets over 5 years: stood at $347.0 million in 2021, then gained by 22.72% to $425.8 million in 2022, then plunged by 35.34% to $275.3 million in 2023, then soared by 140.07% to $660.9 million in 2024, then sank by 34.05% to $435.9 million in 2025.
- The last three Current Assets figures came in at $435.9 million (Q4 2025), $514.6 million (Q3 2025), and $574.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Autolus Therapeutics | 763.37 Mn | 561.74 Mn | 25.22 Mn | 336.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 336.09 Mn |
| Dec 31, 2025 | 435.92 Mn |
| Sep 30, 2025 | 514.58 Mn |
| Jun 30, 2025 | 574.25 Mn |
| Mar 31, 2025 | 615.77 Mn |
| Dec 31, 2024 | 660.93 Mn |
| Sep 30, 2024 | 718.11 Mn |
| Jun 30, 2024 | 758.60 Mn |
| Mar 31, 2024 | 804.30 Mn |
| Dec 31, 2023 | 275.30 Mn |
| Sep 30, 2023 | 308.38 Mn |
| Jun 30, 2023 | 355.37 Mn |
| Mar 31, 2023 | 393.89 Mn |
| Dec 31, 2022 | 425.77 Mn |
| Sep 30, 2022 | 212.31 Mn |
| Jun 30, 2022 | 258.96 Mn |
| Mar 31, 2022 | 309.46 Mn |
| Dec 31, 2021 | 346.95 Mn |
| Sep 30, 2021 | 237.68 Mn |
| Jun 30, 2021 | 269.51 Mn |